Table 3.

Improved Endoscopic and Histologic Response and Remission After Ustekinumab Use in All Patients With Available Data (n = 51), Median 144 Days (Range 56–557), Including a Subset of Refractory Patients With Prior Anti-TNF and Vedolizumab Use (n = 18), Median 120 Days (Range 70, 480)

	All Ustekinumab Patients (n = 51)	Subset of Refractory Patients (n = 18)
Endoscopic response	35 (68%)	10 (56%)
Endoscopic remission	13 (25%)	3 (17%)
Histologic response	29 (57%)	9 (50%)
Histologic remission	13 (25%)	4 (22%)